Arovella Therapeutics Limited

Equities

ALA

AU0000182784

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:46 2024-04-19 am EDT			5-day change	1st Jan Change
0.105 ^AUD	-8.70%		-4.55%	-8.70%

Mar. 26	Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	MT
Mar. 20	Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	MT

Suda Pharmaceuticals Ltd Appoints Michael Baker as A Director

June 28, 2020 at 10:08 pm EDT

Suda Pharmaceuticals Ltd. announced that SUD 's CEO, Dr. Michael Baker, has been appointed as a director to the Board, effective 1 July 2020. Dr. Baker joined SUDA as the CEO on 2 January 2020 as announced on 27 November 2019. Dr. Baker was employed to drive the development of the business and will continue to look for new opportunities for the Company. Dr. Baker's remuneration will remain unchanged.

Latest news about Arovella Therapeutics Limited

Arovella Therapeutics Receives Firm Commitments for About AU$12.5 Million Raise	Mar. 25	MT
Arovella Therapeutics' ALA-101-onCARlytics Collaboration with Imugene Ends; Shares Down 12%	Mar. 19	MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 27	CI
Arovella Boosts Solid Tumor Pipeline with Novel CAR-iNKT Cell Armouring Tech License	Jan. 30	MT
Arovella Therapeutics Manufactures GMP-Grade Lentiviral Vector for Cancer Therapy Product; Shares Climb 4%	Jan. 01	MT
Arovella Therapeutics Ltd. Announces Change of Company Address	Dec. 06	CI
Arovella Therapeutics Appoints CFO	Dec. 01	MT
Arovella Therapeutics Limited Announces Changes to its Board	Nov. 30	CI
Arovella Therapeutics Limited Announces Executive Changes	Nov. 30	CI
Arovella Therapeutics Secures AU$2 Million Tax Rebate for Fiscal Year 2023	Nov. 20	MT
Australian Shares Flat With Positive Bias Amid Hopes of US Fed Keeping Rates Steady	23-10-12	MT
Arovella Therapeutics Secures License for Tumor Targeting Antibody; Shares Fall 6%	23-10-11	MT
Arovella Therapeutics Limited Announces Retirement of David Simmonds as Non-Executive Director	23-09-06	CI
Arovella Therapeutics Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Arovella Therapeutics Raises AU$2.2 Million From Oversubscribed Share Purchase Plan	23-07-11	MT
Arovella Therapeutics Extends Closing Date of Share Purchase Plan	23-06-29	MT
Arovella Therapeutics, UNC Further Discussions on Enhanced iNKT Cells Performance	23-06-26	MT
Arovella Therapeutics Ends AU$4.1 Million Placement; Launches AU$1 Million Purchase Plan	23-06-07	MT
Arovella Therapeutics Completes Closure of Perth R&D Facility	23-05-01	MT
Arovella Therapeutics Appoints Nonexecutive Chair	23-03-13	MT
Arovella Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-22	CI
Arovella, Imugene's Collaboration on Tumor Cells Therapy Progresses to Next Phase	23-02-10	MT
Arovella Therapeutics Limited and Imugene Announces Collaboration Advances to Next Phase of Testing	23-02-09	CI
Arovella Therapeutics Appoints COO	23-01-03	MT
Arovella Therapeutics Ltd Appoints Dr. Nicole Van Der Weerden as Chief Operating Officer, January 4, 2023	23-01-03	CI

Chart Arovella Therapeutics Limited

Duration

Period

More charts

Company Profile

Arovella Therapeutics Limited is a biotechnology company. The Company is focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumors. The Company's lead product is ALA-101. ALA-101 is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. ALA-101 is a next-generation CAR-iNKT cell therapy that targets CD19+ B cell lymphomas and leukemias. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. The Company is also engaged in expanding solid tumor treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Its iNKT cells also contain an invariant T cell receptor (iTCR) that targets alpha-galactosylceramide (a-GalCer) bound CD1d, another antigen found on the surface of several cancer types.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AROVELLA THERAPEUTICS LIMITED	-8.70%	77.77M
IQVIA HOLDINGS INC.	-1.82%	41.35B
LONZA GROUP AG	+42.44%	40.38B
MODERNA, INC.	+2.56%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.36B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.68B
MEDPACE HOLDINGS, INC.	+22.12%	11.6B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.15B

Other Biotechnology & Medical Research